Idelalisib, the first PI3Kδ inhibitor in clinical use, has excellent activity in patients with chronic lymphocytic leukaemia and indolent B-cell lymphomas, heralding a new era of targeted therapy for these types of cancer. Idelalisib intercepts critical communications between B cells and the microenvironment, including B-cell receptor signalling and chemokine networks.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Journal of Hematology & Oncology Open Access 27 April 2022
-
Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies
Journal of Hematology & Oncology Open Access 23 August 2021
-
Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
Leukemia Open Access 27 July 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Friedberg, J. W. et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115, 2578–2585 (2010).
Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32–42 (2013).
Gopal, A. K. et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1314583.
Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1315226.
Okkenhaug, K. et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297, 1031–1034 (2002).
Srinivasan, L. et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573–586 (2009).
Fruman, D. A. & Rommel, C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13, 140–156 (2014).
Burger, J. A. & Gribben, J. G. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin. Cancer Biol. 24, 71–81 (2014).
Burger, J. A. & Chiorazzi, N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 34, 592–601 (2013).
Hoellenriegel, J. et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118, 3603–3612 (2011).
Acknowledgements
The study was supported by a Cancer Prevention and Research Institute of Texas (CPRIT) grant (to J.A.B.), and a Leukemia & Lymphoma Society Scholar Award in Clinical Research (to J.A.B.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.A.B. received research funding from Gilead and Pharmacyclics. K.O. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Burger, J., Okkenhaug, K. Idelalisib—targeting PI3Kδ in patients with B-cell malignancies. Nat Rev Clin Oncol 11, 184–186 (2014). https://doi.org/10.1038/nrclinonc.2014.42
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.42
This article is cited by
-
Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression
Drugs (2023)
-
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Journal of Hematology & Oncology (2022)
-
Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies
Journal of Hematology & Oncology (2021)
-
Transformed follicular lymphoma
Annals of Hematology (2018)
-
Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
Leukemia (2017)